Encysive To Cut U.S. Work Force By 70 Percent To Curb Cash Flow
This article was originally published in The Pink Sheet Daily
Company also appoints George Cole to CEO, replacing Bruce Given, following on the heels of an FDA “approvable” letter for Thelin.
You may also be interested in...
Company asserts that FDA’s data analysis of STRIDE-2 trial for Thelin does not follow special protocol assessment agreement.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
The FIGARO-DKD cardiovascular outcomes trial showed finerenone reduced composite risk of CV death or non-fatal events in CKD patients with Type 2 diabetes, including earlier-stage patients.